SCP Annual Meeting 2027
SCP Annual Meeting 2027 — the premier gathering for critical care pharmacists covering ICU pharmacotherapy, CRRT dosing, sepsis pharmacology, neurocritical care, vasopressors, and sedation/analgesia protocols.
About SCP and Critical Care Pharmacy
The Society of Critical Care Pharmacists (SCP) ↗ is the only US professional organisation dedicated exclusively to critical care pharmacy. SCP members practice in medical, surgical, cardiac, neurocritical, and paediatric ICUs across the country, serving as medication safety experts on multidisciplinary teams alongside physicians, nurses, and respiratory therapists.
The annual meeting is the field's flagship education event, offering ACPE-accredited continuing pharmacy education (CPE) across tracks in pharmacokinetics, antimicrobial stewardship, cardiothoracic pharmacotherapy, neurocritical care, and clinical research. SCP partners closely with the Society of Critical Care Medicine (SCCM) ↗ and co-develops guidelines including the landmark Surviving Sepsis Campaign ↗.
2027 Scientific Tracks
Vancomycin AUC-guided dosing, beta-lactam continuous/extended infusion, MIPD platforms, Bayesian dose optimisation in ICU patients with altered PK.
Surviving Sepsis Campaign 2025 updates, source control pharmacotherapy, combination vs monotherapy in gram-negative sepsis, antifungal dosing in critical illness.
Norepinephrine vs vasopressin for distributive shock, angiotensin II place in therapy, inotrope selection (dobutamine, milrinone), vasopressor weaning strategies.
Status epilepticus treatment algorithms, ICP management pharmacology (hypertonic saline vs mannitol), reversal of antithrombotic agents, post-cardiac arrest care.
PADIS bundle implementation, propofol vs dexmedetomidine in long-term ICU sedation, opioid minimisation strategies, delirium prevention pharmacology.
Practical CRRT dosing principles for aminoglycosides, vancomycin, piperacillin-tazobactam, and antifungals — effluent rate adjustments, SLED vs iHD dosing differences.
PK Alterations in Critical Illness
Critical illness profoundly alters pharmacokinetics. Clinicians cannot rely on standard population PK parameters for ICU patients. Key changes:
| Parameter | Direction in Critical Illness | Mechanism | Drug Example |
|---|---|---|---|
| Vd (hydrophilic) | ↑ (often 2–4×) | Fluid resuscitation, capillary leak, third-spacing | Vancomycin, aminoglycosides |
| Protein binding | ↓ | Hypoalbuminaemia, displacement by fatty acids | Phenytoin, valproate, warfarin |
| Renal clearance | ↑ or ↓ | ARC in early sepsis; AKI in late/severe | Meropenem, piperacillin |
| Hepatic clearance | ↓ | Reduced hepatic blood flow, CYP downregulation | Midazolam, propofol infusion syndrome |
| GI absorption | ↓ or absent | Reduced gut motility, enteral feeding interactions | Oral antibiotics, antifungals |
Sources: Roberts et al. Crit Care 2013 ↗ · NCBI Critical Care Pharmacotherapy ↗